Director Gregory Austin Ciongoli filed a Form 4 with the SEC on August 27, 2026, disclosing three equity transactions in REGENXBIO Inc. common stock between August 25 and August 27, 2026, along with a stock option grant.
Key Highlights
- RSU award: Ciongoli received 15,432 shares of common stock underlying a time-based restricted stock unit award on August 25, 2026, at $0.00 cost, vesting in equal thirds on August 25, 2027, August 25, 2028, and August 25, 2029.
- Open-market purchase (Aug. 26): Ciongoli purchased 49,196 shares at a weighted average price of $9.1411, with individual trades ranging from $8.67 to $9.35.
- Open-market purchase (Aug. 27): Ciongoli purchased 53,407 shares at a weighted average price of $9.356, with individual trades ranging from $9.17 to $9.4525.
- Stock option grant: Ciongoli received options to purchase 69,609 shares of common stock at an exercise price of $8.91, granted August 25, 2026, with expiration on August 25, 2036.
- Total beneficial ownership: Following the reported transactions, Ciongoli directly held 118,035 shares of common stock and 69,609 stock options.
REGENXBIO Director's Multi-Day Equity Activity in August 2026
According to the filing, Gregory Austin Ciongoli, identified as a Director of REGENXBIO Inc. (NASDAQ:RGNX), reported a series of transactions spanning August 25 through August 27, 2026. On August 25, Ciongoli acquired 15,432 shares at no cost representing shares underlying a restricted stock unit award. The filing states that one-third of the RSU shares will vest on each of August 25, 2027, August 25, 2028, and August 25, 2029, subject to the recipient's continuous service to the issuer.
On August 26, 2026, the filing discloses an open-market purchase of 49,196 shares at a weighted average price of $9.1411, executed across multiple trades at prices between $8.67 and $9.35. The following day, August 27, 2026, Ciongoli purchased an additional 53,407 shares at a weighted average price of $9.356, with individual trade prices ranging from $9.17 to $9.4525. The filing notes that full information on the number of shares and prices for each trade is available upon request to the SEC staff, the issuer, or a security holder.
Also on August 25, 2026, Ciongoli was granted stock options to purchase 69,609 shares of common stock at an exercise price of $8.91 per share, expiring August 25, 2036. According to the filing, the option vests over a three-year period, with one-third vesting on August 25, 2027, and the remaining portion vesting in equal monthly installments over the 24 months thereafter, contingent on continuous service. The form was signed by Patrick J. Christmas as attorney-in-fact on August 27, 2026.
What Was Disclosed
The filing reports three common stock acquisitions and one stock option grant by REGENXBIO Director Gregory Austin Ciongoli between August 25 and August 27, 2026, bringing his direct beneficial ownership to 118,035 shares and 69,609 options.



Please wait processing your request...